Nycomed kicks off global market launch of new COPD drug Daxas in Germany
Independent Swiss drugmaker Nycomed started to roll out its new chronic obstructive pulmonary disease (COPD) treatment Daxas (roflumilast) yesterday, noting that it the first new substance class in the area of COPD in more than a decade. The drug was approved in Europe a couple of months ago (The Pharma Letter July 7) but has so far failed to gain clearance from the US Food and Drug Administration (TPL May 18).
Yesterday, Stefan Brinkmann, managing director of Nycomed GmbH, kicked off the German market launch of Daxas in Oranienburg, which is to be the global production center for the drug, making Germany the first country to market the medicine. Daxas is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.
To be marketed in Germany with MSD
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze